Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services

Is Eloralintide legal in India?

Not approvedNot approved in India; Lilly's eloralintide (LY3841136) is only in CDSCO-permitted Phase III trials

Not approved as a medicine here.

Eloralintide has no CDSCO marketing permission. In February and March 2026 CDSCO's expert committee recommended permission for Eli Lilly Phase III trial protocols for LY3841136, the development code for eloralintide, in India. Trial permission is not approval to sell. Under the New Drugs and Clinical Trials Rules, 2019, a drug that the Central Licensing Authority has not approved is a 'new drug' and may not be made for sale or distribution without permission, and CDSCO has used this rule to direct State Drug Controllers to act against other unapproved products (for example, enclomiphene in August 2026).

Last verified 2026-09-29 · how we verify

Eloralintide elsewhere

Sources (3)

  1. 01Recommendations of the SEC (Endocrinology & Metabolism) made in its 03th/26 meeting held on 05.02.2026 at CDSCO HQCentral Drugs Standard Control Organisation (CDSCO), Subject Expert Committee · 2026-02-05 · accessed 2026-09-29
  2. 02Recommendations of the SEC (Pulmonary) made in its 04th/26 meeting held on 23.03.2026 at CDSCO HQCentral Drugs Standard Control Organisation (CDSCO), Subject Expert Committee · 2026-03-23 · accessed 2026-09-29
  3. 03Manufacturing and marketing of unapproved drug products containing Enclomiphene and its combinations (sets out the New Drugs rule for unapproved products)Central Drugs Standard Control Organisation (CDSCO) · 2026-08-10 · accessed 2026-09-29